ABSTRACT
Vaccination against influenza and Streptococcus pneumoniae is recommended for elderly and immunocompromised individuals. However, there is little information concerning the efficacy of vaccination in specific groups of patients. In this study, 52 patients underwent vaccination against influenza, S. pneumoniae and Haemophilus influenzae type b (Hib) as they attended hospital outpatient clinics. Serum was analysed prior to vaccination and 4-6 weeks afterwards. Antibody titres against S. pneumoniae and Hib were compared with reference values corresponding to the geometric mean titres of a healthy UK population. For influenza vaccination, haemagglutination inhibition (HI) titres were measured against three inactivated strains; a titre of > or = 1/40 was considered protective. No patient had protective titres to all three antigens prior to vaccination and 41 patients (85%) had titres < 1/40 to all 3 strains. Post vaccination only 9/48 patients (19%) achieved protective antibody titres. Resistance to S. pneumoniae and response to Pneumovax II was also poor: prevaccination, 45 patients (93%) had suboptimal antibody titres and in 26/43 patients (61%) titres remained low post vaccination. Resistance to Hib and response to vaccination was comparable with the healthy adult UK population. These results question the practice of routine influenza and pneumococcal vaccination in myeloma patients.
Subject(s)
Haemophilus Infections/prevention & control , Haemophilus Vaccines/immunology , Influenza Vaccines/immunology , Multiple Myeloma/immunology , Pneumococcal Infections/prevention & control , Adult , Aged , Antibody Formation , Female , Haemophilus influenzae/immunology , Humans , Immunocompromised Host , Male , Middle Aged , Pneumococcal Infections/immunology , Streptococcus pneumoniae/immunology , VaccinationABSTRACT
Visceral leishmaniasis (VL) is a well recognized opportunistic infection in patients with HIV-1 infection, which may occasionally present with atypical features. We describe two patients with advanced HIV-1 infection (CD4<100/ mm3) in whom visceral leishmaniasis presented with atypical features, and their response to therapy. Atypical features of visceral leishmaniasis in the two infected patients include absence of fever, dissemination to the duodenal mucosa and to the skin as xanthoma-like lesions. Therapy and secondary prophylaxis remain unsatisfactory, and studies to evaluate combinations of amphotericin B and immunotherapy are needed.
Subject(s)
AIDS-Related Opportunistic Infections , Antiprotozoal Agents/therapeutic use , HIV-1 , Leishmaniasis, Visceral , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/parasitology , AIDS-Related Opportunistic Infections/pathology , Adult , Amphotericin B/therapeutic use , Animals , Humans , Leishmania/ultrastructure , Leishmaniasis, Visceral/drug therapy , Leishmaniasis, Visceral/parasitology , Leishmaniasis, Visceral/pathology , Male , Treatment OutcomeABSTRACT
Autologous peripheral blood haemopoietic stem cells (PBSC) were harvested from 30 patients with de novo acute leukaemia, 29 of whom had entered remission following standard chemotherapy. Correlation of CD34+ cells/kg to CFU-GM/kg in the harvests was good (correlation coefficient = 0.72, P < 0.001). We demonstrated significant associations between the CFU-GM content of the harvest and the following: time to platelets >50 x 10(9)/l post final induction course (P < 0.001), days to harvest from day 1 of intensification/mobilization (correlation coefficient = -0.73, P < 0.001), platelets >20 x 10(9)/l at time of harvest (P = 0.02), time to WBC >1.0 x 10(9)/l post intensification/mobilization (correlation coefficient = -0.70, P < 0.001), and WBC on day of harvest (correlation coefficient = 0.60, P < 0.001). In contrast, we found no relationship between the CFU-GM content of the harvest and patient age up to 65 years, presence of absence of coexistent features of trilineage myelodysplasia at diagnosis, number of induction courses to remission or total number of courses of chemotherapy prior to intensification/mobilization. Haemopoietic recovery after reinfusion of PBSC was highly correlated to the number of CFU-GM infused (neutrophils >0.5 x 10(9)/l rs = -0.72, P = 0.001; platelets >20 x 10(9)/l unsupported rs = -0.71, P = 0.001). Our results show that the number of induction courses received, and thus exposure to cytotoxic agents received, made no significant difference to subsequent CFU-GM harvest content. We collected superior harvests from those patients with faster platelet recovery following mobilization therapy. We also found that faster platelet recovery following the final induction therapy was a better predictor of the CFU-GM harvest following mobilization than was the neutrophil recovery following final induction.
Subject(s)
Granulocyte-Macrophage Colony-Stimulating Factor/analysis , Hematopoietic Stem Cell Mobilization/methods , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/chemistry , Leukemia, Myeloid/therapy , Acute Disease , Adolescent , Adult , Antineoplastic Agents, Alkylating/therapeutic use , Busulfan/therapeutic use , Cyclophosphamide/therapeutic use , Female , Humans , Leukocyte Count , Male , Middle Aged , Neutrophils , Platelet Count , Tretinoin/therapeutic useABSTRACT
A case of idiopathic myelofibrosis presenting with a pleural effusion secondary to extramedullary haemopoeisis is described. Approximately 2 years following the diagnosis of his myeloprolioferative disorder the patient presented with dyspnoea. Physical signs were consistent with a pleural effusion which was confirmed radiologically. Cytology of the effusion fluid demonstrated myeloid precursors, including megakaryocytes. The effusion required repeated draining and a pleurodesis was undertaken in an attempt to prevent reaccumulation of the fluid. The procedure was successful and follow up over a period of 5 months demonstrated no recurrence of the pleural effusion on that side of the chest. An effusion later occurred on the other side but was managed conservatively by drainage. Hydroxyurea was introduced at that stage, but shortly afterwards the patient died from an unrelated cause. We review the literature on this uncommon complication of myelofibrosis and discuss the options available to treat the disorder.
Subject(s)
Hematopoiesis, Extramedullary , Hydroxyurea/therapeutic use , Pleural Effusion/etiology , Pleurodesis , Primary Myelofibrosis/therapy , Humans , Male , Middle Aged , Primary Myelofibrosis/etiologySubject(s)
Leukemia/therapy , Acute Disease , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation , Combined Modality Therapy , Cytogenetics , Growth Substances/therapeutic use , Humans , Immunophenotyping , Leukemia/classification , Prognosis , Survival Analysis , Treatment OutcomeABSTRACT
We have previously described a case of clonality switch in a female patient with acute myeloid leukemia (AML) by X-chromosome inactivation analysis. She presented with refractory anemia with excess blasts in transformation but soon progressed to overt AML. Following induction chemotherapy, she went into complete remission but later relapsed into a second myelodysplastic phase. Analysis of her X-linked DNA polymorphism patterns at presentation and relapse showed that hematopoiesis was clonal, but the genotypes of the two clones was different. She remains clinically well and has a virtually normal blood count more than 5 years from presentation. We now report an update of this unique case and discuss the implications of this finding within the context of a multicellular origin of leukemia.
Subject(s)
Anemia, Refractory, with Excess of Blasts/pathology , Clone Cells/pathology , Leukemia, Myeloid, Acute/pathology , Neoplastic Stem Cells/pathology , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Blast Crisis/pathology , Bone Marrow/pathology , Cyclophosphamide/administration & dosage , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Disease Progression , Dosage Compensation, Genetic , Female , Hematopoiesis , Heterozygote , Humans , Leukemia, Myeloid, Acute/drug therapy , Prednisolone/administration & dosage , Remission Induction , Thioguanine/administration & dosage , Vincristine/administration & dosageSubject(s)
Karyotyping , Leukemia, Myeloid/genetics , Leukemia, Myeloid/pathology , Acute Disease , Clone Cells , Hematopoiesis , HumansABSTRACT
Twenty three allogeneic bone marrow transplant (BMT) patients with female donors and 23 female autologous transplant patients were assessed for clonality status after transplant to determine the nature of haemopoietic reconstitution. The X chromosome probes PGK, HPRT and M27 beta were used to assess clonality by analysis of X chromosome inactivation. Results were obtained for 15 allogeneic patients, 14 of whom gave polyclonal results after transplantation. One patient gave a skewed pattern of X chromosome inactivation after transplant due to extreme Lyonisation of the donor cells. Results were obtained from 19 autologous transplant patients, 17 of whom gave polyclonal results after transplant. Two patients gave patterns of skewed X chromosome inactivation in post-transplant samples, reflected in their constitutive DNA, due to extreme Lyonisation. The remaining patients could not be assessed because of hypermethylation of HpaII sites or indistinguishable digested and undigested alleles using M27 beta probe analysis. Haemopoietic reconstitution after allogeneic and autologous BMT, in our patients, was found to be polyclonal. Skewed patterns of X chromosome inactivation seen after transplant were due to extreme Lyonisation of the infused haemopoietic cells.
Subject(s)
Bone Marrow Transplantation , Dosage Compensation, Genetic , Leukemia/genetics , Female , Hematopoiesis , Humans , Leukemia/blood , Leukemia/therapy , Polymorphism, Genetic , Transplantation, Autologous , Transplantation, HomologousABSTRACT
Multiple myeloma is a neoplastic disorder caused by the proliferation of a transformed B lymphoid progenitor cell that gives rise to a clone of immunoglobulin-secreting cells. Other plasma cell tumours include solitary plasmacytoma of bone (SPB) and extramedullary plasmacytomas (EMP). Despite an apparent common origin there exist pathological and clinical differences between these neoplasms and the association between them is not completely understood. A case of IgG multiple myeloma that presented with typical clinical and laboratory features, including a bone marrow infiltrated by well differentiated plasma cells, is reported. The tumour had an unusual evolution, with the development of extensive extramedullary disease while maintaining mature histological features.
Subject(s)
Multiple Myeloma/pathology , Plasma Cells/pathology , Aged , Humans , Kidney/diagnostic imaging , Male , Multiple Myeloma/diagnostic imaging , Neoplasm Invasiveness , Pancreas/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
Clonal haemopoiesis has previously been demonstrated in some 30% of patients in remission of acute myeloid leukaemia (AML). Whilst a 'clonal remission' in many such patients may represent a skewed X-chromosome inactivation pattern in haemopoietic cells, its relationship to an underlying preleukaemic state remains uncertain. We therefore analysed the clonal status of 48 female patients in remission of AML using X-chromosome linked restriction fragment length polymorphisms (RFLPs) within the X-linked PGK and HPRT genes and the DXS255 (M27 beta) locus, and carried out in conjunction a detailed study of the morphological and karyotypic features of the patients' bone marrows. During remission, 35 patients (73%) with AML demonstrated nonclonal haemopoiesis, and their bone marrows were morphologically normal. Remission haemopoietic tissue in nine cases (19%) showed a skewed X-chromosome inactivation pattern and remission bone marrows in these patients had features of trilineage myelodysplasia (TMDS), with seven having similar features at presentation. Analysis of constitutional DNA showed a non-clonal pattern in seven of these patients, but was unsuccessful in two cases. These nine patients with post-chemotherapy TMDS were considered to have true clonal haemopoiesis. Four patients (8%) with a skewed X-chromosome inactivation pattern had normal remission bone marrows. Analysis of constitutional DNA showed a skewed pattern in two of these patients, but was unsuccessful in two cases. Cytogenetic investigation during remission in the nine patients with TMDS showed a normal karyotype in four cases and the acquisition of new karyotypic abnormalities in three cases. In contrast, 10 female patients in remission of de novo acute lymphoblastic leukaemia (ALL) were shown to have non-clonal haemopoiesis. We conclude that the majority of patients with AML who achieve remission after cytoreductive chemotherapy have non-clonal haemopoiesis, and when clonal remissions are observed these are commonly associated with the development of trilineage myelodysplasia in the bone marrow, with or without karyotypic abnormalities. True clonal remission in association with morphologically normal haemopoiesis is a rare entity, the significance and frequency of which remain uncertain.
Subject(s)
Bone Marrow/pathology , Hematopoietic Stem Cells/pathology , Leukemia, Myeloid, Acute/pathology , Myelodysplastic Syndromes/pathology , Aged , Blotting, Southern , Dosage Compensation, Genetic , Female , Hematopoiesis , Humans , Middle Aged , Polymorphism, Restriction Fragment Length , Remission InductionABSTRACT
We have used a recombinant strategy based on X-chromosome-linked restriction fragment length polymorphisms to analyze clonality in a female patient with acute myeloid leukemia (AML). She presented with features compatible with a diagnosis of refractory anemia with excess of blasts in transformation, but soon progressed into overt AML. Intensive chemotherapy successfully induced a complete remission, but she later relapsed into a second myelodysplastic phase. Although analysis at presentation and relapse showed that hematopoiesis was clonal at both phases of the patient's disease, the genotype of the two clones was different. We believe the unexpected finding of a switch in clonality shows new insights into the biology and origin of AML.
Subject(s)
Clone Cells/pathology , Leukemia, Myeloid, Acute/genetics , Myelodysplastic Syndromes/genetics , Neoplasm Recurrence, Local/genetics , Polymorphism, Restriction Fragment Length , X Chromosome , Adult , Bone Marrow/pathology , Deoxyribonuclease BamHI , Deoxyribonucleases, Type II Site-Specific , Female , Humans , Hypoxanthine Phosphoribosyltransferase/genetics , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/pathology , Myelodysplastic Syndromes/pathology , Remission InductionABSTRACT
Experimental work in animal models suggests that the course of systemic and organ-specific autoimmune disorders can be modified by allogeneic bone marrow transplantation (BMT). We describe two patients, each with a long history of psoriasis and ulcerative colitis, who received an allogeneic BMT for leukaemia. Four years post-BMT, they remain in full remission of psoriasis and ulcerative colitis, and of their leukaemia. We review the evidence for support of the concept that both psoriasis and ulcerative colitis are immune-mediated disorders and speculate on the possible role of allogeneic BMT in treating life-threatening autoimmune disorders.